Alembic Pharmaceuticals Reports Robust Q2 FY27 Results with 81% PAT Growth
Alembic Pharmaceuticals Ltd · Investor Presentation · 04 Nov 2026, 8:08 pm
Alembic Pharmaceuticals Reports Robust Q2 FY27 Results with 81% PAT Growth Alembic Pharmaceuticals delivered strong Q2 FY27 performance, with revenue growing 36% YoY to ₹26.03 bn, driven by double-digit expansion across all segments: US formulations surged 77% YoY to ₹10.03 bn, API grew 39% to ₹4.36 bn, India branded rose 14% to ₹7.25 bn, and Ex-US climbed 12% to ₹4.40 bn. EBITDA surged 78% YoY to ₹5.78 bn as EBITDA margins expanded 520 bps to 22%, while PAT attributable to shareholders jumped 81% YoY to ₹3.35 bn. R&D spend stood at 8% of revenue.
Original exchange filing (PDF)
More announcements from Alembic Pharmaceuticals Ltd
- Alembic Pharmaceuticals Limited receives USFDA Final Approval for Binimetinib Tablets, 15 mg and 45 mg. · 15 Nov 2026
- Please find attached herewith the Transcript of Post Results Conference Call held on 4th November, 2026. · 10 Nov 2026
- Alembic Pharmaceuticals Limited receives USFDA Final Approval for Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% (OTC). · 05 Nov 2026
- Please find attached Audio Recording of Investor Call. · 05 Nov 2026
- Please find attached intimation under Regulation 30(5) of SEBI (LODR) Regulations, 2015. · 04 Nov 2026
- Please find attached Press Release · 04 Nov 2026
- Please find attached Press Release for the Quarter and Half Year Ended September 30, 2026. · 04 Nov 2026
- Please find attached Unaudited Financial Results for the Quarter and Half Year Ended September 30, 2026. · 04 Nov 2026
